Multi-scale wrinkles for functional alignment of stem cells and cardiac derivatives

Patent metadata

Field	Value
Publication number	US-9452564-B2
Application number	US-201213654275-A
Country	US
Kind code	B2
Filing date	Oct 17, 2012
Priority date	Feb 7, 2011
Publication date	Sep 27, 2016
Grant date	Sep 27, 2016

Abstract

Provided are methods of preparing a biocompatible textured surface on a thermoplastic material comprising treating the material with a plasma and subsequently shrinking the substrate to induce formation of textures. The textured surfaces are useful in one aspect, to align cells such as stem cells.

First claim

What is claimed is:

1. A plurality of cells aligned on nanoscale wrinkles or textures on a surface of a thermoplastic material, wherein the wrinkles or textures are prepared by a method comprising:
treating a surface of a thermoplastic material with a plasma to increase the stiffness of an outer layer of the surface relative to a subsurface layer,
constraining two opposite sides of the plasma-treated thermoplastic material, and
shrinking the constrained plasma-treated thermoplastic material under conditions to buckle the outer layer to form a surface with nanoscale wrinkles or textures relative to the subsurface layer of the material.

2. The plurality of cells of claim 1 , wherein the cells are selected from fibroblasts, cardiac cells or cardiomyocytes.

3. The plurality of cells of claim 2 , wherein the cells are derived from a plurality of stem cells.

4. The plurality of cells of claim 3 , wherein the stem cells are one or more of iPSC, embryonic stem cells, an embryoid body or pluripotent stem cells.

5. The plurality of cells of claim 4 , wherein the stem cells are human stem cells.

6. The plurality of cells of claim 1 , wherein the plasma-treated nano-textured surface has been treated with plasma for a period from about 0.5 minutes to 30 minutes.

7. The plurality of cells of claim 1 , wherein the plasma is one or more of oxygen plasma, helium plasma or hydrogen plasma.

8. The plurality of cells of claim 3 , wherein the cells are cardiomyocytes derived from stem cells and wherein the cardiomyocytes exhibit an anisotropic ratio of from about 1.5 to about 2.5 or a measurable action potential.

Assignees

• Univ California

Inventors

• Khine Michelle
• Li Ronald A
• Chen Cheng-Wei

Classifications

• B29C59/14 Primary

  by plasma treatment {(plasma tubes per se H01J)} · CPC title

• B29C61/02

  Thermal shrinking · CPC title